Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya64216710.26442/00403660.2025.12.203468Case reportsКлинические наблюденияResearch ArticleA clinical case of erythromelalgia in a patient comorbid with antiphospholipid syndromeКлинический случай эритромелалгии у коморбидной пациентки с антифосфолипидным синдромомhttps://orcid.org/0000-0003-0160-6015KudrjavtsevaAnna A.КудрявцеваАнна Александровна
Russian Federation

ассистент каф. факультетской терапии №1

Ankudr@bk.ruhttps://orcid.org/0009-0007-0815-0627MeladzeArina V.МеладзеАрина Валериановна
Russian Federation

студентка Института клинической медицины им. Н.В. Склифосовского

Ankudr@bk.ruhttps://orcid.org/0000-0003-1274-4667TrapeznikovaEkaterina S.ТрапезниковаЕкатерина Сергеевна
Russian Federation

студентка Института клинической медицины им. Н.В. Склифосовского

Ankudr@bk.ruhttps://orcid.org/0000-0002-9315-3801LevshinaAnna R.ЛевшинаАнна Романовна
Russian Federation

ординатор

Ankudr@bk.ruhttps://orcid.org/0000-0001-6241-2711NapalkovDmitry A.НапалковДмитрий Александрович
Russian Federation

д-р мед. наук, проф. каф. факультетской терапии №1

Ankudr@bk.ruhttps://orcid.org/0000-0001-5938-8917SokolovaAnastasiya A.СоколоваАнастасия Андреевна
Russian Federation

д-р мед. наук, проф. каф. факультетской терапии №1

Ankudr@bk.ruSechenov First Moscow State Medical University (Sechenov University)ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)National Medical Research Centre for Therapy and Preventive MedicineФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава России140220269712Vario (various)Vario (разное)101810222311202422092025Copyright ©; 2026, Consilium MedicumCopyright ©; 2026, ООО "Консилиум Медикум"2026Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/642167

The article presents a clinical case of secondary erythromelalgia in a comorbid patient with antiphospholipid syndrome, accompanied by burning pain, hyperemia and swelling of the lower extremities. A comprehensive examination involving a neurologist, dermatologist, and rheumatologist was conducted to establish the diagnosis and select the optimal therapy. Significant clinical improvement in the patient's condition is demonstrated against the background of pregabalin therapy. The importance of a multidisciplinary approach and the difficulty of diagnosis due to the lack of specific examination methods and insufficient awareness of doctors about this disease are emphasized. The described case demonstrates the need for a personalized approach to managing patients with erythromelalgia to improve their quality of life.

В статье представлен клинический случай вторичной эритромелалгии у коморбидной пациентки с антифосфолипидным синдромом, сопровождающейся жгучей болью, гиперемией и отеком нижних конечностей. Представлено комплексное обследование пациентки с привлечением невролога, дерматолога и ревматолога для установки диагноза и подбора оптимальной терапии. Продемонстрировано значимое клиническое улучшение состояния пациентки на фоне терапии прегабалином. Подчеркивается важность мультидисциплинарного подхода и трудность диагностики, обусловленные отсутствием специфических методов обследования и недостаточной осведомленностью врачей о таком заболевании. Описанный случай демонстрирует необходимость персонализированного подхода к ведению пациентов с эритромелалгией для улучшения качества их жизни.

erythromelalgiaantiphospholipid syndromeMitchell syndromeacrocyanosisburning painSCN9A gene mutationsNav1.7 sodium channelscomorbid patientclinical caseэритромелалгияантифосфолипидный синдромсиндром Митчеллаакроцианозжгучая больмутации в гене SCN9Aнатриевые каналы Nav1.7коморбидный пациентклинический случайTang Z, Chen Z, Tang B, Jiang H. Primary erythromelalgia: a review. Orphanet J Rare Dis. 2015;10(1):127. DOI:10.1186/s13023-015-0347-1Davis MD, O’Fallon WM, Rogers RS 3rd, Rooke TW. Natural History of Erythromelalgia: Presentation and Outcome in 168 Patients. Arch Dermatol. 2000;136(3):330-6. DOI:10.1001/archderm.136.3.330Davis MD. Facial erythromelalgia? J Am Acad Dermatol. 2018;78(5):e127. DOI:10.1016/j.jaad.2017.10.056Rovensky J, Payer J. Erythromelalgia: Dictionary of Rheumatology. Springer Vienna. 2009;62. DOI:10.1007/978-3-211-79280-3_348Dib-Hajj SD, Rush AM, Cummins TR, et al. Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain. 2005;128(Pt. 8):1847-54. DOI:10.1093/brain/awh514Mann N, King T, Murphy R. Review of primary and secondary erythromelalgia. Clin Exp Dermatol. 2019;44(5):477-82. DOI:10.1111/ced.13891Cohen JS. Erythromelalgia: New theories and new therapies. J Am Acad Dermatol. 2000;43(5 Pt. 1):841-7. DOI:10.1067/mjd.2000.109301Farrar MA, Lee MJ, Howells J, et al. Burning pain: axonal dysfunction in erythromelalgia. Pain. 2017;158(5):900-11. DOI:10.1097/j.pain.0000000000000856Meents JE, Bressan E, Sontag S, et al. The role of Nav1.7 in human nociceptors: insights from human induced pluripotent stem cell-derived sensory neurons of erythromelalgia patients. Pain. 2019;160(6):1327-41. DOI:10.1097/j.pain.0000000000001511Насонов Е.Л., Решетняк Т.М., Соловьев С.К., Попкова Т.В. Системная красная волчанка и антифосфолипидный синдром: вчера, сегодня, завтра. Терапевтический архив. 2023;95(5):365-74 [Nasonov E, Reshetnyak T, Solovyev S, Popkova Т. Systemic lupus erythematosus and antiphospholipid syndrome: past, present, future. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(5):365-74 (in Russian)]. DOI:10.26442/00403660.2023.05.202246Buttaci CJ. Erythromelalgia: A Case Report and Literature Review. Pain Med. 2006;7(6):534-8. DOI:10.1111/j.1526-4637.2006.00240.xKurzrock R, Cohen PR. Erythromelalgia: Review of clinical characteristics and pathophysiology. Am J Med. 1991;91(4):416-22. DOI:10.1016/0002-9343(91)90160-yDavis MD, Wilkins F, Rooke TW. Between Episodes of Erythromelalgia: A Spectrum of Colors. Arch Dermatol. 2006;142(8):1065. DOI:10.1001/archderm.142.8.1085Asigo G, Parry SJ. Mental health and social sequelae of a rare condition: erythromelalgia. Prog Neurol Psychiatry. 2023;27(2):21-3. DOI:10.1002/pnp.788Fan H, Yu W, Zhang Q, et al. Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2014;39(4):334-42. DOI:10.1111/jcpt.12167Kanbay M, Kaya A, Bozalan R, et al. Gabapentin Induced Edema in A Geriatric Patient. Clin Neuropharmacol. 2006;29(3):186. DOI:10.1097/01.WNF.0000204279.09291.ACKahlon A, Gnanabakthan N, Dhillon A, Subedi D. A rare case of bilateral lower extremity edema due to low dose gabapentin therapy in a young male patient. J Basic Clin Pharm. 2015;6(4):117. DOI:10.4103/0976-0105.168053Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2011;(3):CD007938. DOI:10.1002/14651858.CD007938.pub2Wallace MS, Irving G, Cowles VE. Gabapentin Extended-Release Tablets for the Treatment of Patients with Postherpetic Neuralgia: A Randomized, Double-Blind, Placebo-Controlled, Multicentre Study. Clin Drug Investig. 2010;30(11):765-76. DOI:10.2165/11539520-000000000-00000Parsons B, Tive L, Huang S. Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. Am J Geriatr Pharmacother. 2004;2(3):157-62. DOI:10.1016/j.amjopharm.2004.09.004Bidaki R, Sadeghi Z, Shafizadegan S, et al. Gabapentin induces edema, hyperesthesia and scaling in a depressed patient; a diagnostic challenge. Adv Biomed Res. 2016;5:1. DOI:10.4103/2277-9175.174955Hou JL, Onajin O, Gangat N, et al. Erythromelalgia in patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma. 2017;58(3):715-7. DOI:10.1080/10428194.2016.1205740Cummins TR, Dib-Hajj SD, Waxman SG. Electrophysiological Properties of Mutant Nav 1.7 Sodium Channels in a Painful Inherited Neuropathy. J Neurosci. 2004;24(38):8232-6. DOI:10.1523/JNEUROSCI.2695-04.2004McDonnell A, Schulman B, Ali Z, et al. Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile. Brain. 2016;139(Pt. 4):1052-65. DOI:10.1093/brain/aww007Davis MD, Weenig RH, Genebriera J, et al. Histopathologic findings in primary erythromelalgia are nonspecific: Special studies show a decrease in small nerve fiber density. J Am Acad Dermatol. 2006;55(3):519-22. DOI:10.1016/j.jaad.2006.04.067Kalgaard OM, Clausen OP, Mellbye OJ, et al. Nonspecific Capillary Proliferation and Vasculopathy Indicate Skin Hypoxia in Erythromelalgia. Arch Dermatol. 2011;147(3):309-14. DOI:10.1001/archdermatol.2010.337Clarke JTR. Narrative Review: Fabry Disease. Ann Intern Med. 2007;146(6):425-33. DOI:10.7326/0003-4819-146-6-200703200-00007Skeik N, Rooke TW, Davis MD, et al. Severe case and literature review of primary erythromelalgia: Novel SCN9A gene mutation. Vasc Med. 2012;17(1):44-9. DOI:10.1177/1358863X11422584Davis MD. Immersion foot associated with the overuse of ice, cold water, and fans: A distinctive clinical presentation complicating the syndrome of erythromelalgia. J Am Acad Dermatol. 2013;69(1):169-71. DOI:10.1016/j.jaad.2013.02.021Davis MD, Sandroni P. Lidocaine Patch for Pain of Erythromelalgia. Arch Dermatol. 2002;138(1):17-9. DOI:10.1001/archderm.138.1.17Gales A, Chaaban B, Husson H, et al. Lidocaine-medicated plaster for treating acute autonomic and sensory neuropathy with erythromelalgia-like presentations. Rev Neurol (Paris). 2016;172(6–7):399-400. DOI:10.1016/j.neurol.2016.03.004Sandroni P, Davis MD. Combination Gel of 1% Amitriptyline and 0.5% Ketamine to Treat Refractory Erythromelalgia Pain: A New Treatment Option? Arch Dermatol. 2006;142(3):283-6. DOI:10.1001/archderm.142.3.283Poterucha TJ, Weiss WT, Warndahl RA, et al. Topical amitriptyline combined with ketamine for the treatment of erythromelalgia: a retrospective study of 36 patients at Mayo Clinic. J Drugs Dermatol. 2013;12(3):308-10.Muhiddin KA, Gallen IW, Harries S, Pearce VR. The use of capsaicin cream in a case of erythromelalgia. Postgrad Med J. 1994;70(829):841-3. DOI:10.1136/pgmj.70.829.841Kurzrock R, Cohen PR. Erythromelalgia and myeloproliferative disorders. Arch Intern Med. 1989;149(1):105-9.Krishnan SG, Yesudian DP, Jayaraman M, et al. Erythromelalgia responding to aspirin. Indian J Dermatol Venereol Leprol. 1996;62(3):204-5.McGraw T, Kosek P. Erythromelalgia Pain Managed with Gabapentin. Anesthesiology. 1997;86(4):988-90. DOI:10.1097/00000542-199704000-00029Natkunarajah J, Atherton D, Elmslie F, et al. Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel. Clin Exp Dermatol. 2009;34(8):640-2. DOI:10.1111/j.1365-2230.2009.03355.xKalava K, Roberts C, Adair JD, Raman V. Response of Primary Erythromelalgia to Pregabalin Therapy. J Clin Rheumatol. 2013;19(5):284-5. DOI:10.1097/RHU.0b013e31829cf8a2Kakizaki A, Fujimura T, Kambayashi Y, et al. Successful Treatment of Adult-Onset Erythromelalgia with Steroid Pulse and Pregabalin. Case Rep Dermatol. 2012;4(3):242-6. DOI:10.1159/000345377DiCaudo DJ, Kelley LA. Alleviation of erythromelalgia with venlafaxine. Arch Dermatol. 2004;140(5):621-3. DOI:10.1001/archderm.140.5.621Herskovitz S, Loh F, Berger AR, Kucherov M. Erythromelalgia: Association with hereditary sensory neuropathy and response to amitriptyline. Neurology. 1993;43(3 Pt. 1):621-2. DOI:10.1212/WNL.43.3_Part_1.621Pagani-Estevez GL, Sandroni P, Davis MD, Watson JC. Erythromelalgia: Identification of a corticosteroid-responsive subset. J Am Acad Dermatol. 2017;76(3):506-11. DOI:10.1016/j.jaad.2016.08.048Durosaro O, Davis MD, Hooten WM, Kerkvliet JL. Intervention for Erythromelalgia, a Chronic Pain Syndrome: Comprehensive Pain Rehabilitation Center, Mayo Clinic. Arch Dermatol. 2008;144(12):1578-83. DOI:10.1001/archdermatol.2008.515